Staphylococcus Aureus / AZD7760 · Phase 1/2 Trial

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

ClinicalTrials.gov · August 14, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 1/2a study of AZD7760, an intravenous drug, evaluating safety and pharmacokinetics in healthy volunteers and patients with end-stage renal disease on hemodialysis. No results have been reported in this registry record; the study is currently recruiting.

What was studied

Phase 1/2, Interventional, Randomized, Parallel, Quadruple masking, Prevention purpose. Staphylococcus Aureus; age from 18 Years; to 55 Years; accepts healthy volunteers. Intervention: Phase I: AZD7760 Dose A; Phase I: AZD7760 Dose B; Phase I: AZD7760 Dose C; Phase IIa: AZD7760 Dose D and Placebo; Phase IIa: AZD7760 Dose E. Compared with: Phase I: Placebo — Placebo Comparator; Phase IIa: Placebo — Placebo Comparator. n = 231. 44 sites: United States.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This is an early-phase trial with no results yet available. Clinicians and researchers should monitor for completion and results posting to evaluate whether AZD7760 demonstrates an acceptable safety profile and favorable pharmacokinetics in renal-impaired populations.

Plain-language summary

This is a Phase 1/2a clinical trial registry record with no reported results; it describes a planned study of safety and pharmacokinetics in healthy adults and dialysis patients, currently recruiting.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Phase I: Occurence of adverse events (AEs) (assessed at Day 1 to Day 181); Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) (assessed at Day 1 to Day 361); Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs (assessed at Day 1 to Day 181)

DesignPhase 1/2, Interventional, Randomized, Parallel, Quadruple masking, Prevention purpose

PopulationStaphylococcus Aureus; age from 18 Years; to 55 Years; accepts healthy volunteers

Sample size231

InterventionPhase I: AZD7760 Dose A; Phase I: AZD7760 Dose B; Phase I: AZD7760 Dose C; Phase IIa: AZD7760 Dose D and Placebo; Phase IIa: AZD7760 Dose E

ComparatorPhase I: Placebo — Placebo Comparator; Phase IIa: Placebo — Placebo Comparator

Setting44 sites: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment231

Phase I primary outcomeOccurrence of adverse events (AEs), Day 1 to Day 181

Phase I extended outcomeOccurrence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs), Day 1 to Day 361

Phase IIa primary outcomeOccurrence of AEs, MAAEs, SAEs, and AESIs, Day 1 to Day 181

Clinical bottom line

Caveats

No results have been reported in this registry record; all statements describe planned outcomes only.
Phase-specific sample sizes not provided; 231 is total estimated enrollment across both phases.
Blinding and allocation concealment methods not described in registry record.
Recruitment status is RECRUITING; study is not yet complete and no efficacy data are available.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Two-phase interventional design with placebo control; Phase 1 in healthy volunteers, Phase 2a in ESRD on hemodialysis.

Directness

moderate

Primary outcomes are safety and PK; clinical utility for Staph aureus infection not yet established in this registry entry.

Consistency

insufficient

Registry record only; no results reported; consistency cannot be assessed.

Risk of bias

insufficient

Placebo-controlled design noted but blinding status, allocation concealment, and conduct details not stated in registry.

Sample adequacy

moderate

Planned enrollment 231 participants across two phases; Phase-specific breakdowns not provided in registry record.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06749457). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 231 participants (ESTIMATED). Conditions: Staphylococcus Aureus. Interventions: DRUG: AZD7760; OTHER: Placebo. Primary outcome measures: Phase I: Occurence of adverse events (AEs) , Day 1 to Day 181; Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) , Day 1 to Day 361; Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs , Day 1 to Day 181. Brief summary: The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Staphylococcus AureusNCT06749457AZD7760AstraZeneca